Thank you for reading

Curing hereditary blindness with CRISPR-Cas without cutting the DNA

Inherited blindness can be treated with a safe gene therapy approach using activation of functionally equivalent genes.
In a proof of principle study, researchers show how 'dead' dCas9 fused to transcriptional activators can 'wake' silent genes to alleviate hereditary blindness in a mouse model of retinitis pigmentosa.
The therapeutic strategy offers safer gene therapy without cutting the DNA and risking indel-type off-target effects, as is a major concern with the classical CRISPR-Cas system.
Read our story and interview with lead researcher Elvir Becirovic here.

Thank you for now - more great reads are on the way!

And if you have questions or suggestions, you can reach out to us directly at editor@crisprmedicinenews.com. We love hearing from readers!

(c; Rasmus

p.s. You can follow CRISPR Medicine News on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up for our newsletter yourself here.